BioCapZ: A Highly Efficient Capsid-Based Nano-Platform for Non-Invasive Theranostics Delivery

Authors

  • Mo. A. Baikoghli Department of Molecular and Cellular Biology, University of California, Davis, CA, USA and Institute for Molecular Medicine, (FIMM), Hi Life, University of Helsinki, Finland.
  • Chun-Chieh Chen Astrid Pharma Corp., Davis, CA, USA.
  • R. Holland Cheng Department of Molecular and Cellular Biology, University of California, Davis, CA, USA.

DOI:

https://doi.org/10.9734/bpi/cpms/v4/2482A

Keywords:

Protein capsid, hepatitis e vlp, BioCapZ, nanoparticle, cancer diagnosis, cancer treatment, site-specific delivery, mucosal delivery, non-invasive delivery

Abstract

Through nanotechnology, progressively, drug delivery, cancer treatment, and vaccination are moving towards personalization. With personalized and precision medicine being one of the major focus points of nanotechnology and nanopharmacological studies these days, there is a great need for an efficient nanocarrier delivery system with no toxicity and high capacity for modularization. Several nanocarrier systems have been introduced comprising both natural and synthetic material; however, overcoming biological barriers, toxicity, targeting accuracy, and encapsulation efficiency remain a challenge. Here we summarize the latest breakthroughs of protein-capsid-based nanocarrier, BioCapZ, as a nano-platform for non-invasive delivery for vaccines, gene editors, imaging agents, and theranostics.

Published

2022-06-22

How to Cite

Mo. A. Baikoghli, Chun-Chieh Chen, & R. Holland Cheng. (2022). BioCapZ: A Highly Efficient Capsid-Based Nano-Platform for Non-Invasive Theranostics Delivery. Current Practice in Medical Science Vol. 4, 140–147. https://doi.org/10.9734/bpi/cpms/v4/2482A